Role of von Willebrand Factor (vWF) and ADAMTS-13 Protease in Hemorrhagic and Thrombotic Disorders: Clinical Implications in Neonates with Oncological Diseases

Authors

DOI:

https://doi.org/10.71248/r356vz02

Keywords:

von Willebrand Factor, Neoplasms, ADAMTS13 Protein, Infant, Newborn, Thrombosis

Abstract

The study investigates the role of von Willebrand factor (vWF) and the protease ADAMTS-13 in hemostasis, with a focus on neonates with oncological diseases. This is an integrative literature review carried out in the Scopus, ScienceDirect and Embase databases. The results indicate that the interaction between vWF and ADAMTS-13 is essential for hemostatic balance, and its deregulation can lead to hemorrhagic and thrombotic complications in these patients. In cancer neonates, high levels of vWF and reduced ADAMTS-13 activity increase the risk of thrombosis, especially under inflammatory conditions or treatments such as chemotherapy. In addition, studies highlight the importance of monitoring these factors to prevent adverse events. It is concluded that understanding this relationship may contribute to more effective therapeutic strategies, reducing complications and improving the prognosis of neonates with câncer.

Author Biographies

  • Jaydes Schultz Fuly, Faculdade Medicina Petrópolis – FMP

    Graduando em Medicina

  • Romaryo Mareco Alves de Sá, Unifsm

    Graduado em Medicina

  • Isadora Walber Machado, Universidade de Passo Fundo - UPF

    Graduanda em Medicina

     

  • Hellen Lorrany Barbosa de Sousa, Universidade Estadual do Rio de Janeiro - UERJ
    • Graduada em Medicina
  • Guilherme Dalla Chiesa, Universidade de Caxias do Sul - UCS

    Graduando em Medicina

     

  • Yana Queiroz Rodrigues, Universidade Estadual do Sudoeste da Bah

    Graduada em Farmácia

  • Júlia Muraro Marchetti, Pontifícia Universidade Católica do Rio Grande do Sul – PUCRS

    Graduanda em Medicina

     

  • Ana Livia Ferreira Pissinatti, FMPFM

    Graduada em Medicina

  • Nadyme Assef Athayde Mubarac, Estácio do Amazonas

    Pós-Graduanda em Farmácia

     

  • Rafaela de Souza Lopes , Universidade do Estado do Rio de Janeiro

    Graduada em Medicina

     

  • Marcos Roberto Fernandes , Faculdade de Ciências Biomédicas de Cacoal - FACIMED

    Graduado em Medicina, Pós-Graduado em Pedriatria

  • Maria Eduarda Pereira Riberto Fávero, Pontifícia Universidade Católica de Minas Gerais - Campus Poços de Caldas

    Graduanda em Medicina

References

1. Cagnolati D, Kumar Sankarankutty A, Plínio Souza Rocha J, Beer A, Castro Silva O. Hemostasia e distúrbios da coagulação [Internet]. 2015 [citado 27 de novembro de 2024]. Disponível em: https://sites.usp.br/dcdrp/wp-content/uploads/sites/273/2017/05/hemostasia_revisado.pdf

2. Tonaco LC, Rios DRA, Vieira LM, Carvalho M das G, Dusse LMS. Púrpura trombocitopênica trombótica: o papel do fator von Willebrand e da ADAMTS13. Rev Bras Hematol Hemoter. 2010;32(2):155–61.

3. Santos M, Paiva M, Macedo C, Petrilli A, Azeka E, Jatene I, et al. I Diretriz Brasileira de Cardio-Oncologia Pediátrica da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2013;100(5):01–68.

4. Lopes LF, Camargo B de, Bianchi A. Os efeitos tardios do tratamento do câncer infantil. Rev Assoc Med Bras. setembro de 2000;46(3):277–84.

5. Sena TS, Pinheiro Filho SR, Lyra IM. Distúrbios da hemostasia em crianças portadoras de cardiopatias congênitas. Rev Bras Hematol Hemoter. 2010;32(2):149–54.

6. Alpoim PN. Pré-eclâmpsia: avaliação de fator VIII, fator de Von Willebrand e Adamts-13 e do grupo sanguíneo ABO. Universidade Federal de Minas Gerais [Internet]. 2010 [citado 27 de novembro de 2024]; Disponível em: http://hdl.handle.net/1843/NCFA-8DATYY

7. Dantas HL de L, Costa CRB, Costa L de MC, Lúcio IML, Comassetto I. Como elaborar uma revisão integrativa: sistematização do método científico. Revista Recien - Revista Científica de Enfermagem. 13 de março de 2022;12(37):334–45.

8. Dong J fei, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 1o de dezembro de 2002;100(12):4033–9.

9. Katneni UK, Ibla JC, Hunt R, Schiller T, Kimchi‐Sarfaty C. von Willebrand factor/ADAMTS‐13 interactions at birth: implications for thrombosis in the neonatal period. Journal of Thrombosis and Haemostasis. março de 2019;17(3):429–40.

10. Lambers M, Goldenberg NA, Kenet G, Kirkham FJ, Manner D, Bernard T, et al. Role of reduced ADAMTS13 in arterial ischemic stroke: A Pediatric Cohort Study. Ann Neurol. 7 de janeiro de 2013;73(1):58–64.

11. Nguyen TC, Liu A, Liu L, Ball C, Choi H, May WS, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica. 1o de janeiro de 2007;92(1):121–4.

12. Schmugge M, Dunn MS, Amankwah KS, Blanchette VS, Freedman J, Rand ML. The activity of the von Willebrand factor cleaving protease ADAMTS‐13 in newborn infants. Journal of Thrombosis and Haemostasis. fevereiro de 2004;2(2):228–33.

13. Molvarec A, Rigó Jr J, Bõze T, Derzsy Z, Cervenak L, Makó V, et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost. 23 de novembro de 2009;101(02):305–11.

14. Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. Journal of Thrombosis and Haemostasis. dezembro de 2018;16(12):2375–90.

15. Karampinis I, Nowak K, Koett J, Mess C, Wagner L, Gaiser T, et al. Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality. Haematologica. 22 de setembro de 2022;108(1):261–6.

16. Hunt R, Hoffman CM, Emani S, Trenor CC, Emani SM, Faraoni D, et al. Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease. Journal of Thrombosis and Haemostasis. dezembro de 2017;15(12):2306–16.

17. Zhou Z, Jing H, Tao Z, Choi H, Aboulfatova K, Moake J, et al. Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13. Thromb Res. julho de 2009;124(3):323–7.

18. Frere C, Mazzeffi M, Maier CL, Helms J, Steiner ME, Sullenger BA, et al. Acquired von Willebrand syndrome during extracorporeal membrane oxygenation support: a comprehensive review of current evidence: communication from the ISTH SSC on perioperative and critical care thrombosis and hemostasis. Journal of Thrombosis and Haemostasis. setembro de 2024;22(9):2608–28.

19. Davidesko S, Pikovsky O, Al-Athamen K, Hackmon R, Erez O, Miodownik S, et al. von Willebrand factor antigen: a biomarker for severe pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura? Journal of Thrombosis and Haemostasis. junho de 2023;21(6):1623–9.

20. Saldanha A, Colella MP, Villaça PR, Thachil J, Orsi FA. The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP? Thromb Res. setembro de 2024;241:109109.

21. Strauss T, Elisha N, Ravid B, Rosenberg N, Lubetsky A, Levy-Mendelovich S, et al. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates. Blood Cells Mol Dis. setembro de 2017;67:14–7.

22. Drop JG, Wildschut ED, de Maat MPM, van Rosmalen J, de Boode WP, de Hoog M, et al. Acquired von Willebrand disease in children undergoing extracorporeal membrane oxygenation: a prospective observational study. Journal of Thrombosis and Haemostasis. dezembro de 2023;21(12):3383–92.

23. PEYVANDI F, PALLA R, LOTTA LA, MACKIE I, SCULLY MA, MACHIN SJ. ADAMTS‐13 assays in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. abril de 2010;8(4):631–40.

Downloads

Published

2025-01-30

Issue

Vol. 2 No. 1 (2025)

Section

Artigos

License

Copyright (c) 2025 Cognitus Interdisciplinary Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Role of von Willebrand Factor (vWF) and ADAMTS-13 Protease in Hemorrhagic and Thrombotic Disorders: Clinical Implications in Neonates with Oncological Diseases. (2025). Cognitus Interdisciplinary Journal, 2(1), 83-96. https://doi.org/10.71248/r356vz02

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.